Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (34212)	3/26/2010 12:10:32 AM
From: Robohogs	2 Recommendations Read Replies (1) \| Respond to of 52153

I don't get how repackaging data can help their cause - smells of ad hoc unplanned statistical hypothesizing to me. And the bigger set of Ph 2 data was safety, right? And the panel had efficacy issues as well as safety issues. And it's not like FDA would ignore the earlier safety data in coming to its conclusions/worries. Here is the twitter chain from Adam F. twitter.com Quite entertaining to follow some back to comments from others. adamfeuerstein 1. $CTIC will be fun to see how Jimbo cuts burn rate in half to $4M/month. Jimbo flies coach? Greyhound bus? fire everyone except his brother? about 7 hours ago via TweetDeck 2. @Bigd7007 like @ldtimmerman said -- 30 minutes of my life i will never get back. I need a shower after that call. about 7 hours ago via TweetDeck 3. $CTIC -- owners of the $40M debt due July refused 2 go along with co's debt tender offer last yr. They ain't gonna just roll over now, jimbo about 7 hours ago via TweetDeck 4. I didn't bother to get in line --> RT @BiotechStockRsr: $CTIC - We were still in the Q&A queue. How about you? about 7 hours ago via TweetDeck 5. $CTIC -- go steve! you're a dumbass for owning the stock but i liked your speech. about 7 hours ago via TweetDeck 6. RT @ldtimmerman: This $CTIC conf call--about 20 mins of my life that I'll never get back about 7 hours ago via TweetDeck 7. $CTIC -- Bianco mentions $NVS -- i win!!! about 7 hours ago via TweetDeck 8. @johnwelshphd I'm listening.... and laughing. $CTIC about 7 hours ago via TweetDeck in reply to johnwelshphd 9. @BiotechStockRsr I guess i'm tired of teaching on $CTIC. the students don't listen. about 7 hours ago via TweetDeck in reply to BiotechStockRsr 10. $CTIC -- it's embarassing that we focus so much on a worthless stock. I'm as guilty of that as anyone. about 8 hours ago via TweetDeck 11. $CTIC -- Bianco will find a way to mention $NVS, if only to goose the buyout speculation. about 8 hours ago via TweetDeck 12. $CTIC conference call @ 5 pm. Pass the popcorn... about 8 hours ago via TweetDeck

To: rkrw who wrote (34212)	3/31/2010 1:59:17 AM
From: Ian@SI	1 Recommendation Read Replies (2) \| Respond to of 52153

Another $20M to survive with... Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants prnews SEATTLE, March 31 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA:CTIC) (the "Company") today announced that it has entered into an agreement to sell $20 million of shares of its Series 4 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors. Each share of Series 4 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,000 shares of common stock at a conversion price of $0.50 per share of common stock, for a total of 40,000,000 common shares. In connection with the offering, the investors received warrants to purchase up to 20,000,000 shares of common stock. The warrants have an exercise price of $0.6029 per warrant share, for total potential additional proceeds to the Company of approximately $12 million upon exercise of the warrants. The warrants are exercisable six months after issuance and terminate four years after the date of issuance. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications, and general working capital. Shares of the Series 4 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters. The closing of the offering is expected to occur on April 6, 2010, at which time the Company will receive the cash proceeds and deliver the securities.